Search clinical trials for: AZD8055

Total 47 results

AstraZeneca

Withdrawn

AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers

Healthy
National Cancer Institute (NCI)

Completed

AZD8055 for Adults With Recurrent Gliomas

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Brainstem Glioma

United States
AstraZeneca

Completed

A Study of Tor Kinase Inhibitor in Advanced Tumors

Solid Tumors

United States, France, United Kingdom
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

Healthy Participants

United States
AstraZeneca

Completed

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Idiopathic Pulmonary Fibrosis

United States
AstraZeneca

Terminated

AZD8075 Single Ascending Dose Study

Healthy Volunteers

Sweden
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients

Cancer | Advanced Hepatocellular Carcinoma

Korea, Republic of, Hong Kong
AstraZeneca

Completed

AZD0585 Phase III Long-term Study in Japan

Hypertriglyceridemia

Japan
AstraZeneca
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.

Asthma

Germany
AstraZeneca

Completed

A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects

Healthy

Japan
AstraZeneca

Completed

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
AstraZeneca

Withdrawn

Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

Cancer | Advanced Solid Tumours | Lymphomas
AstraZeneca
Parexel

Completed

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

Healthy Volunteers

United States
AstraZeneca

Completed

AZD9056 Relative Bioavailability Study

Healthy

United Kingdom
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
AstraZeneca

Recruiting

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Breast Cancer | Ovarian Cancer | Endometrial Cancer | Biliary Tract Carcinoma

United States, Spain, Australia, United Kingdom, Korea, Republic of, Belgium, Canada, China, Japan, Taiwan, Thailand, Hungary, Poland, Netherlands
AstraZeneca

Terminated

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

Thrombin Inhibition

United States
AstraZeneca

Completed

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

GERD With Erosive Esophagitis

Sweden, United States, France, Italy, United Kingdom, Germany, Denmark, Finland, Norway, Canada
AstraZeneca

Active, not recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.

Heathy Participants

Japan
AstraZeneca

Completed

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

GERD Without Erosive Esophagitis

Sweden, United States, France, Italy, United Kingdom, Germany, Denmark, Finland, Norway, Canada
AstraZeneca
Parexel

Terminated

A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

Healthy Subjects

United Kingdom
AstraZeneca

Completed

Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056

Rheumatoid Arthritis

United Kingdom
National Taiwan University Hospital
Ministry of Science and Technology, Taiwan

Unknown

Lesogaberan in Chinese Patients With Refractory Reflux Symptoms

Gastroesophageal Reflux Disease

Taiwan
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
AstraZeneca
Parexel

Withdrawn

A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen

Asthma

Canada
AstraZeneca

Completed

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Corona Virus Disease

United States
AstraZeneca

Completed

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Advanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation

United States, United Kingdom
AstraZeneca

Terminated

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 (ENDURE)

Coronavirus Disease 2019 (COVID-19)

United States
AstraZeneca
ImaginAb, Inc.

Terminated

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Colorectal Cancer

United States, Canada
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); AstraZeneca; University of... and other collaborators

Active, not recruiting

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

COVID-19

United States, Denmark, Greece, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
AstraZeneca

Completed

Study to Compare Different Formulations of AZD3355

Gastroesophageal Reflux Disease

Sweden
AstraZeneca

Completed

A Study to Assess Co-Administered AZD9056 (Steady State) and Simvastatin (Single Dose) in Healthy Volunteers

Healthy Volunteers

Germany
AstraZeneca

Completed

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE)

COVID-19

United States, Spain, United Kingdom, Brazil, Germany, Ukraine, Japan, Italy, Poland, Russian Federation, Mexico, Czechia, Argentina, Hungary, Peru
AstraZeneca

Completed

TLESR-impedance Study in Patients

Reflux Episodes
AstraZeneca

Completed

Renal Impairment Study

Reflux | Renal Excretion

Sweden
AstraZeneca

Completed

AZD3355 Dose-escalation Study in Healthy Males

Reflux Disease

Sweden
AstraZeneca

Completed

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

Gastroesophageal Reflux Disease

United States
AstraZeneca

Completed

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

Gastroesophageal Reflux Disease (GERD)

Hungary, Romania, Norway, Belgium, France, Netherlands, Germany, Australia
AstraZeneca

Completed

Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms (C27)

GERD | Heartburn | Acid Reflux Disease | Regurgitation

United States
AstraZeneca

Completed

Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI

Gastroesophageal Reflux Disease | Heartburn | Regurgitation

United States
AstraZeneca

Completed

Drug Interaction Study Between AZD3355 and Nexium

Gastroesophageal Reflux Disease

Sweden
National Institute of Allergy and Infectious Diseases...
Eli Lilly and Company; National Heart, Lung, and Blood Institute (NHLBI); Gla... and other collaborators

Completed

ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO)

Covid19

United States, Denmark, Greece, Nigeria, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
AstraZeneca

Completed

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States, Mexico, Poland, Romania, Canada, Argentina, Australia, Slovakia, France, Czech Republic, Belgium, Russian Federation
AstraZeneca

Withdrawn

A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients

Rheumatoid Arthritis
Pablo Tebas
AstraZeneca; Inovio Pharmaceuticals; The Wistar Institute

Recruiting

dMAbs for Prevention of COVID-19

Healthy Volunteers

United States
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada

Search clinical trials for: AZD8055

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations